绝经症状激素替代治疗与心脏代谢疾病风险:现有证据与未来方向
这是一篇叙述性综述,围绕绝经期激素替代治疗(HRT)对心脏代谢危险因素及冠心病、卒中和代谢相关脂肪性肝病风险的影响展开。文章指出雌激素给药途径、启动时机和孕激素类型均可能影响HRT的多种心脏代谢结局。现有证据提示HRT可能影响内脏脂肪堆积、血脂、血压和血糖控制,但部分领域仍存在不确定性。
要点
- HRT用于控制绝经症状,但需同时讨论其对心脏代谢的影响以辅助决策。
- 雌激素给药途径、启动时机和孕激素类型可能改变HRT的心脏代谢效应。
- HRT对代谢相关脂肪性肝病的影响研究较少,属未来研究方向。
核心结论
- 现有证据提示HRT可能影响内脏脂肪堆积、血脂谱、血压和血糖控制等代谢危险因素的发展。
- HRT对冠心病和卒中等心脏代谢结局的影响已被随机对照试验进一步阐明,但部分结论仍存不确定性。
- 雌激素给药途径、启动时机和孕激素类型可能影响HRT对多种心脏代谢结局的作用。
- 绝经对代谢相关脂肪性肝病的发生和严重程度有影响,但HRT背景下的研究仍很少。
研究设计与样本
- 研究设计为叙述性综述。
- 文章讨论既有证据和临床指南,不涉及原始样本量或统计数值。
主要发现
- 绝经过渡期伴随一系列不良代谢变化,与中年后女性心脏代谢疾病风险增加相关。
- 随机对照试验结果完善了HRT对冠心病和卒中影响的认识。
- 近期研究强调绝经对代谢相关脂肪性肝病发生和严重程度的影响。
- 部分国家媒体对HRT关注增加,导致处方率上升,理解HRT心脏代谢风险尤为重要。
关键数值与推荐
- HRT的适应证是控制绝经症状。
- 综述讨论HRT对内脏脂肪堆积、血脂谱不良变化、血压和血糖控制的影响。
- 综述讨论HRT对冠心病、卒中和代谢相关脂肪性肝病风险的影响。
- 综述提出雌激素给药途径、启动时机和孕激素类型可能影响HRT结局。
临床怎么用
- 在启动和继续HRT时,应讨论心脏代谢影响以促进知情决策。
- 选择HRT方案时应考虑雌激素给药途径、启动时机和孕激素类型。
局限性
- 代谢相关脂肪性肝病在HRT背景下研究很少。
- 综述中多个领域仍存在不确定性,需进一步研究确定优先方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Background The transition through menopause is accompanied by a series of adverse metabolic changes which are associated with an increased risk of cardiometabolic disease, a major cause of mortality in women after midlife. Whilst the indication for menopausal hormone replacement therapy (HRT) is the control of menopausal symptoms, understanding and discussing the cardiometabolic impacts of HRT are necessary to facilitate informed decision-making at treatment initiation and continuation, and to select appropriate regimens. Methodology A narrative review. Results Existing evidence suggests that HRT is likely to impact the development of metabolic risk factors including visceral fat accumulation, adverse changes in lipid profile, blood pressure and glycaemic control. Findings from randomised controlled trials have refined our understanding of the impact of HRT on cardiometabolic outcomes including coronary heart disease and stroke. Furthermore, recent research has highlighted the impact of the menopause on the development and severity of metabolic dysfunction-associated steatotic liver disease (MASLD) that has been poorly studied in the context of HRT. The route of oestrogen administration, timing of initiation and type of progestogen are all likely to affect the impact of HRT on many of these outcomes. There has recently been extensive media interest in HRT in some countries resulting in increased prescription rates. Understanding the impact of HRT on cardiometabolic risk is therefore particularly important. In this narrative review, we discuss the existing evidence and clinical guidelines on the effect of HRT on cardiometabolic risk factors and the risk of coronary heart disease, stroke and MASLD, highlighting areas of uncertainty and priorities for further research.
引用
- BJOG:Hormone Replacement Therapy for Menopausal Symptoms and the Risk of Cardiometabolic Disease: Current Evidence and Future Directions
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。